HIKAL LIMITED·PHARMACEUTICALS 70.24CDMO 78.00·Pharmaceuticals & Biotechnology Companies

Price

215.61

+1.57%
O:212.7
H:218.35
L:212.7
C:215.61

52W Range

146.25282.7
+47%/-24%

Market Cap

₹2,658.49 Cr

Traded: ₹3.76 Cr (0.14%) 0.0x

Free Float: ₹609.33 Cr (0.62% of FF traded)

Volume · 60D trend

1.74 L 0.0x

Delivery: % 0.0x

View Delivery Data

Returns

1W:+0% 1M:-3% 3M:+5% 6M:+12% 12M:-15%

Valuation

P/E--
P/B2.2
P/S1.5
EV/EBIT22.4

Business Strength

ROE7.4%
ROCE9.9%
OPM12.8%
NPM-2.9%

Growth (3Y CAGR)

EPS-153.8%
Sales-5.0%
Profit-22.0%
3Y Return-9.0%

Balance Sheet

Debt/Equity0.6
Debt681 Cr
Pledge0.0%
CWIP/Fixed Asset7.1%

Cash Position

CFO/NP-616.3%
FCF154 Cr
FCF 3Y Avg281 Cr
Cash/MCap1.0%

Others

Div Yield0.3%
Div Payout-15.0%
Cash Conv. Cycle138 days
Tradeable Free Float22.9%

MTF Exposure Trend

60 sessions · funded amount, % of FF, daily delta

Current
₹ 43.60 Cr
7.16% FF
60d high
₹ 44.10 Cr
60d low
₹ 30.77 Cr
60d mean
₹ 37.22 Cr
vs mean
▲ 17.14%

Growth Trends

Metric10Y5Y3Y1YTTMTrend
Sales
+6.0%
+0.0%
-5.0%
--
-5.0%
Stable
ROE
+10.0%
+8.0%
+5.0%
--
--
Decelerating
Return
+5.0%
-18.0%
-9.0%
-28.0%
--
Stable
Profit
-1.0%
-23.0%
-22.0%
--
-33.0%
Stable

Quarterly Results

Jun 2026

6 Aug
Rev
403 Cr
+6% YoY-22% QoQ
OPM9.2%
NPM-1.8%
PAT
---7 Cr
EPS
+67% YoY-0.6

Mar 2026

27 May
Rev
519 Cr
-6% YoY+5% QoQ
OPM20.3%
NPM2.8%
PAT
+23% YoY14 Cr
EPS
-71% YoY1.2

Dec 2025

11 Feb
Rev
494 Cr
+10% YoY+55% QoQ
OPM16.7%
NPM-1.2%
PAT
+87% YoY-6 Cr
EPS
-135% YoY-0.5

Sep 2025

PDF
Rev
319 Cr
-30% YoY-16% QoQ
OPM2.3%
NPM-11.0%
PAT
-291% YoY-35 Cr
EPS
-291% YoY-2.8

Jun 2025

PDF
Rev
380 Cr
-6% YoY-31% QoQ
OPM6.6%
NPM-5.9%
PAT
-539% YoY-22 Cr
EPS
-544% YoY-1.8

Mar 2025

PDF
Rev
552 Cr
+7% YoY+23% QoQ
OPM22.3%
NPM9.1%
PAT
+48% YoY50 Cr
EPS
+48% YoY4.1

Dec 2024

PDF
Rev
448 Cr
+0% YoY-1% QoQ
OPM16.1%
NPM3.8%
PAT
+7% YoY17 Cr
EPS
+6% YoY1.4

Sep 2024

PDF
Rev
453 Cr
+4% YoY+11% QoQ
OPM16.5%
NPM4.0%
PAT
+46% YoY18 Cr
EPS
+45% YoY1.5

Jun 2024

PDF
Rev
407 Cr
+5% YoY-21% QoQ
OPM14.3%
NPM1.3%
PAT
-26% YoY5 Cr
EPS
-27% YoY0.4

Mar 2024

PDF
Rev
514 Cr
-6% YoY+15% QoQ
OPM18.4%
NPM6.6%
PAT
-6% YoY34 Cr
EPS
-6% YoY2.8

Dec 2023

PDF
Rev
448 Cr
-17% YoY+3% QoQ
OPM14.5%
NPM3.6%
PAT
-39% YoY16 Cr
EPS
-39% YoY1.3

Sep 2023

PDF
Rev
435 Cr
-22% YoY+12% QoQ
OPM13.2%
NPM2.9%
PAT
-49% YoY13 Cr
EPS
-49% YoY1.0

Jun 2023

PDF
Rev
388 Cr
---29% QoQ
OPM13.0%
NPM1.8%
PAT
+178% YoY7 Cr
EPS
--0.6

Mar 2023

Rev
545 Cr
--+1% QoQ
OPM16.0%
NPM6.6%
PAT
+74% YoY36 Cr
EPS
--2.9

Dec 2022

Rev
540 Cr
---3% QoQ
OPM13.8%
NPM4.9%
PAT
-42% YoY26 Cr
EPS
--2.1

Sep 2022

Rev
559 Cr
----
OPM12.0%
NPM4.5%
PAT
-44% YoY25 Cr
EPS
--2.0

Revenue & Margin Trends

Annual

Quarterly

Balance Sheet Health

Leverage

Debt / Equity0.57
Interest Coverage5.7x
Promoter Pledge0.0%
Borrowings684 Cr

Efficiency

Receivable Days94 days
Inventory Days172 days
Payable Days128 days
Cash Conversion cycle138 days

Cash Position

Operating Cash Flow302 Cr
Investing Cash Flow-145 Cr
Financing Cash Flow-160 Cr
Free Cash Flow154 Cr

Detailed Financials

Jun 2026PDF ↗
Mar 2026PDF ↗
Dec 2025PDF ↗
Sep 2025PDF ↗
Jun 2025PDF ↗
Mar 2025PDF ↗
Dec 2024PDF ↗
Sep 2024PDF ↗
Jun 2024PDF ↗
Mar 2024PDF ↗
Dec 2023PDF ↗
Sep 2023PDF ↗
Jun 2023PDF ↗
Mar 2023
Dec 2022
Sep 2022
Sales403519494319380552448453407514448435388545540559
Expenses366414412311355429376378349420383377338457466489
Operating Profit371058372512372755894655850887570
OPM %9.2%20.3%16.7%2.3%6.6%22.3%16.1%16.5%14.3%18.4%14.5%13.2%13.0%16.0%13.8%12.0%
Other Income11-41-352114011011031
Interest15151615171819192015141314131311
Depreciation43424141393833323232292928272827
Profit Before Tax-108-9-47-30682425747221710493633
Tax %-25.3%-73.5%-35.9%-25.7%-26.3%26.5%27.7%26.2%26.1%28.3%25.5%25.4%28.9%26.0%26.2%24.0%
Net Profit-714-6-35-2250171853416137362625
Exceptional Items---47-38000000000000--
EPS (Rs)-0.61.2-0.5-2.8-1.84.11.41.50.42.81.31.00.62.92.12.0
Sales Growth (YoY)5.9%-6.0%10.4%-29.7%-6.5%7.5%0.0%4.1%4.8%-5.7%-17.2%-22.2%--------
Sales Growth (QoQ)-22.4%5.1%55.2%-16.3%-31.1%23.4%-1.1%11.3%-20.9%14.9%2.9%12.1%-28.8%0.9%-3.4%--
OP Growth (YoY)47.4%-14.6%14.7%-90.4%-56.7%30.7%11.4%30.2%15.3%7.3%-13.2%-17.8%--------
OP Growth (QoQ)-64.9%27.4%1048.6%-71.3%-79.7%71.2%-3.7%29.1%-38.6%45.9%12.5%14.4%-42.8%18.0%6.5%--
Profit Growth (YoY)--23.0%87.0%-291.0%-539.0%48.0%7.0%46.0%-26.0%-6.0%-39.0%-49.0%178.0%74.0%-42.0%-44.0%
EPS Growth (YoY)67.0%-71.3%-134.5%-291.2%-543.9%48.0%6.1%45.1%-26.8%-5.8%-38.8%-49.3%--------
EPS Growth (QoQ)-151.3%343.8%83.0%-55.5%-144.7%192.8%-6.1%261.0%-85.1%109.9%28.4%82.1%-80.8%36.5%6.5%--
OP Margin9.2%20.3%16.7%2.3%6.6%22.3%16.1%16.5%14.3%18.4%14.5%13.2%13.0%16.1%13.8%12.5%
Net Margin-1.8%2.8%-1.2%-11.0%-5.9%9.1%3.8%4.0%1.3%6.6%3.6%2.9%1.8%6.6%4.9%4.5%
Material Cost %--41.7%46.9%39.6%49.1%42.0%47.1%44.6%47.3%45.6%46.2%49.0%43.9%51.3%52.4%56.9%
Employee Cost %--12.9%14.3%21.9%16.5%11.5%14.4%13.7%14.0%12.4%13.7%14.2%15.4%10.6%11.7%10.4%
P/S1.531.681.561.43------------------------
P/E------242.81------------------------
P/B2.222.392.282.03------------------------

Shareholding Pattern

Shareholders:73.5K (-2.2%)
Current MixJun 2026

Exchange Filings

50
Company Update12 Aug 2026

Newspaper Publication regarding Special Window for Transfer and Dematerialization of physical securities

Company Update12 Aug 2026

Transcript of Earnings Conference Call for the quarter ended June 30, 2026

Company Update07 Aug 2026

Newspaper publication for Financial Results of Q1''FY27

Board Meeting06 Aug 2026

Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Company Update06 Aug 2026

Audio Recording of Earnings Group Conference Call for the Quarter ended June 30, 2026.

Company Update06 Aug 2026

Press Release on Q1FY27 Results

Company Update06 Aug 2026

Investor Presentation for Q1FY27

Result06 Aug 2026

Unaudited Financial Results (Standalone & Consolidated) for Quarter ended June 30, 2026.

Company Update09 Jul 2026

Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended June 30, 2026.

AGM/EGM06 Jul 2026

Postal Ballot- Scrutinizer''s Report and Voting Results

AGM/EGM06 Jul 2026

Postal Ballot- Outcome of Postal Ballot (Scrutinizer''s Report and Voting Results)

Insider Trading / SAST25 Jun 2026

Intimation of Closure of Trading Window

Company Update10 Jun 2026

Newspaper Publication regarding Special Window for Transfer and Dematerialisation of Physical Securities

Company Update05 Jun 2026

Intimation of Newspaper Publication of Postal Ballot Notice and remote e- Voting

AGM/EGM04 Jun 2026

Intimation of Postal Ballot notice and remote e-Voting

Company Update30 May 2026

Intimation of copy of reminder letters sent to Shareholders regarding Unclaimed Final Dividend 2018-19 and subsequent Newspaper Publication.

Company Update28 May 2026

Newspaper Publication - Financial Results

Company Update27 May 2026

Reschedule of Analyst meet on Wednesday May 27, 2026 at 5:30 PM.

Company Update27 May 2026

Pursuant to Regulation 30 SEBI (LODR) Regulation 2015- Change in Management

Result27 May 2026

Results- Financial Results for March 31,2 026

Board Meeting27 May 2026

Outcome of Board Meeting

Company Update27 May 2026

Pursuant to Regulation 30 SEBI (LODR) Regulation 2015- Change in Management

Company Update27 May 2026

Announcement under Regulation 30 (LODR)- Updates

Company Update27 May 2026

Pursuant to Regulation 30 SEBI (LODR) Regulations, 2015- Change in Management

Company Update27 May 2026

Announcement under Reg 30 SEBI(LODR)- Investor Presentation

Company Update27 May 2026

Announcement under Regulation 30 (LODR)- Press Release.

Company Update27 May 2026

Analyst Call/Earnings Group Conference call audio recording

Board Meeting20 May 2026

Hikal Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Audited Financial Results (Standalone ....

Company Update20 May 2026

Intimation of Q4 & FY 2026 Earnings Call.

Company Update14 Apr 2026

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Superannuation/Retirement of Senior Management Personnel (SMP).

Company Update10 Apr 2026

Newspaper Publication on Special Window and Second 100-Day Campaign- Saksham Niveshak.

Company Update07 Apr 2026

Pursuant to Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018- Certificate under Regulation 74(5) for the quarter ended March 31, 2026.

Insider Trading / SAST25 Mar 2026

Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, please find attached the intimation of the closure of trading window for the quarter ....

Company Update18 Feb 2026

Intimation Under Regulation 7 (2) of SEBI Prohibition of Insider Trading Regulations, 2015

Others18 Feb 2026

Intimation Under regulation 30 and 30A of SEBI Listing Regulations

Insider Trading / SAST18 Feb 2026

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Castilia Life Sciences LLP

Insider Trading / SAST18 Feb 2026

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Castilia Life Sciences LLP & PACs

Insider Trading / SAST18 Feb 2026

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Castilia Life Sciences LLP & PACs

Company Update17 Feb 2026

Transcript of the earning call for the quarter and nine months ended December 31, 2025

Company Update12 Feb 2026

Kindly find the Communication shared with shareholder

Company Update12 Feb 2026

Please find attached the copy of newspaper publication.

Company Update11 Feb 2026

Intimation of Amendment to the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting Trading by Designated Persons of the Company.

Corp. Action11 Feb 2026

Please find attached the Intimation of record date for Corporate Action

Company Update11 Feb 2026

Please find attached the Intimation of Audio recording of Analyst/Investor Meet

Corp Action11 Feb 2026

Intimation of Record Date

Company Update11 Feb 2026

Please find attached the Press Release

Company Update11 Feb 2026

Please find attached the investor Presentation

Board Meeting11 Feb 2026

Please find attached the outcome of the Board Meeting

Result11 Feb 2026

Please find attached outcome of the Board Meeting

Board Meeting04 Feb 2026

Hikal Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve The unaudited standalone and consolidated ....

Annual Reports

15

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

Credit Ratings

6
icraRating update
24 Nov 2025Report
icraRating update
19 Aug 2025Report
icraRating update
09 Apr 2025Report
icraRating update
04 Mar 2024Report
icraRating update
03 Apr 2023Report
icraRating update

Concalls

34

Feb 2026

28 Feb 2026

Jan 2026

31 Jan 2026

Nov 2025

30 Nov 2025

Sep 2025

30 Sept 2025

Aug 2025

31 Aug 2025

May 2025

31 May 2025

Feb 2025

28 Feb 2025

Nov 2024

30 Nov 2024

Nov 2024

30 Nov 2024

Aug 2024

31 Aug 2024

May 2024

31 May 2024

Feb 2024

29 Feb 2024

Nov 2023

30 Nov 2023

Aug 2023

31 Aug 2023

Jun 2023

30 Jun 2023

Feb 2023

28 Feb 2023

Nov 2022

30 Nov 2022

Aug 2022

31 Aug 2022

Jun 2022

30 Jun 2022

Feb 2022

28 Feb 2022

Oct 2021

31 Oct 2021

Aug 2021

31 Aug 2021

May 2021

31 May 2021

Aug 2020

31 Aug 2020

Oct 2019

31 Oct 2019

Aug 2019

31 Aug 2019

Mar 2019

31 Mar 2019

Nov 2018

30 Nov 2018

May 2018

31 May 2018

Mar 2018

31 Mar 2018

Nov 2017

30 Nov 2017

Jun 2017

30 Jun 2017

Feb 2016

29 Feb 2016

Feb 2016

29 Feb 2016

Held by ETFs

1 ETFs hold hikal · sorted by weight

#ETFWeight %
1

MOHEALTH

MOTILALAMC - MOHEALTH

0.05%

Held by Mutual Funds

4 schemes hold hikal · sorted by weight

#SchemeWeight %
1

Tata Small Cap Fund

Tata Mutual Fund

0.58%
2

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

ICICI Prudential Mutual Fund

1.34%
3

Bandhan BSE Healthcare Index Fund

Bandhan Mutual Fund

0.05%
4

Motilal Oswal BSE 1000 Index Fund

Motilal Oswal Mutual Fund

0.00%